Armata Capex To Operating Cash Flow from 2010 to 2025
| ARMP Stock | USD 1.25 0.09 7.76% |
Capex To Operating Cash Flow | First Reported 2010-12-31 | Previous Quarter (0.05) | Current Value (0.05) | Quarterly Volatility 0.24869525 |
Check Armata Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Armata Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 11.3 M, Selling General Administrative of 12.5 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 28.2, Dividend Yield of 0.0175 or Days Sales Outstanding of 256. Armata financial statements analysis is a perfect complement when working with Armata Pharmaceuticals Valuation or Volatility modules.
Armata | Capex To Operating Cash Flow | Build AI portfolio with Armata Stock |
Latest Armata Pharmaceuticals' Capex To Operating Cash Flow Growth Pattern
Below is the plot of the Capex To Operating Cash Flow of Armata Pharmaceuticals over the last few years. It is Armata Pharmaceuticals' Capex To Operating Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Armata Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Capex To Operating Cash Flow | 10 Years Trend |
|
Capex To Operating Cash Flow |
| Timeline |
Armata Capex To Operating Cash Flow Regression Statistics
| Arithmetic Mean | (0.10) | |
| Geometric Mean | 0.03 | |
| Coefficient Of Variation | (238.73) | |
| Mean Deviation | 0.12 | |
| Median | (0.03) | |
| Standard Deviation | 0.25 | |
| Sample Variance | 0.06 | |
| Range | 1.018 | |
| R-Value | 0.34 | |
| Mean Square Error | 0.06 | |
| R-Squared | 0.11 | |
| Significance | 0.20 | |
| Slope | 0.02 | |
| Total Sum of Squares | 0.93 |
Armata Capex To Operating Cash Flow History
About Armata Pharmaceuticals Financial Statements
Armata Pharmaceuticals shareholders use historical fundamental indicators, such as Capex To Operating Cash Flow, to determine how well the company is positioned to perform in the future. Although Armata Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Armata Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Armata Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capex To Operating Cash Flow | (0.05) | (0.05) |
Additional Tools for Armata Stock Analysis
When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.